"AMBS" - Most undervalued bio-tech stock. - Currently trading under a dime.
Recently announced a deal with Becton Dickinson to develop its diagnostic test to detect early stage Alzheimer's. Potential $500,000,000 annual market. License agreement would move the share price to the .50 range.
The company's patented MANF drug could be worth billions as a treatment for a number of neurological diseases.
Read the recent Yahoo news.
Follow the company on Twitter: @AmarantusBio .... 8,444 followers currently